Latest Breaking News On - எலி மோர்டெச்சை - Page 1 : vimarsana.com

Genesis Drug Discovery and Development Acquires Integrated Analytical Solutions to Add Off the Shelf PK Profiling Capabilities to Its Portfolio News provided by Share this article ® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD 3) announced today that it has acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS). Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, drug metabolism, and analytical chemistry services to clients worldwide. Integrated Analytical Solutions (IAS) Logo This is our second acquisition in the space of two months as we further expand our presence in the San Francisco bay area, which we see as a market with tremendous growth potential for drug discovery services said Eli Mordechai, Ph.D., Chief Executive Officer (CEO) of GBG. Adding IAS s GxP compliant bioanalytical platform to GD

San francisco bayUnited statesPrabal banerjeeEli mordechaiJonah michaelianBen bandaruContract research organizationAnalytical solutions incCorporate developmentGenesis drug discovery developmentAnalytical solutionsGenesis biotechnology groupBusiness developmentGenesis biotechnologyGenesis drug discoverySan francisco